|
|
Vaccine Detail
|
Dendritic Cell Tumor Cell Lysate Vaccine |
| Vaccine Information |
- Vaccine Name: Dendritic Cell Tumor Cell Lysate Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007368
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- ATL1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Immature DCs are pulsed with autologous lysate or homogenate prepared from surgically removed tumour lesions and matured for 48 hours with a cytokine cocktail (tumor necrosis factor alfa, IL-1β, IL-6, and prostaglandin E2) to obtain mature DCs (Ridolfi et al., 2018).
- Description: A vaccine composed of dendritic cells pulsed with tumor cells lysates that stimulate a potent and specific cell mediated anti-tumor immune response. (NCI) (NCIT_C1988).
|
| Host Response |
|
|
| References |
NCIT_C1988: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1988]
Ridolfi et al., 2018: Ridolfi L, de Rosa F, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, Riccobon A, Gentili G, Nanni O, Framarini M, Tauceri F, Guidoboni M. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial). BMJ open. 2018; 8(8); e021701. [PubMed: 30082356].
|
|
